Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Research Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) on Bullrun: market cap CNY 23.45B, P/E 41.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688266.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 23.45B
- P/E41.4
- Financial periodQ2 2026
- RevenueCNY 299.99M
- Net incomeCNY 7.40M
- Free cash flow-CNY 44.52M
- Gross margin87.5%
Valuation Snapshot
latest market cap is CNY 23.45B; P/E is 41.4.
Peer valuation comparison
Latest P/E is 41.4x versus a Healthcare sector median of 21.8x (89.9% above).
Latest P/E is 41.4x versus a China median of 16.46x (151.5% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 23.45B | 41.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CNY.
About Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis.
ETFs that hold Suzhou Zelgen Biopharmaceuticals Co., Ltd.
US-listed ETFs
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is held by 12 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | 0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated June to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s market cap?
Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s market capitalization is CNY 23.45B.
What is Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s P/E ratio?
Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 41.4.
What does Suzhou Zelgen Biopharmaceuticals Co., Ltd. do?
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis.